American healthcare boasts cutting-edge medical technology, yet patients, especially children with neurological disorders, often endure years of symptom management without clear diagnoses—a journey known as the “diagnostic odyssey.” This process not only saps emotional strength from families and clinicians but also drives up enormous costs. A critical yet underused solution is genomic sequencing, which reads the complete genetic blueprint to pinpoint disease causes. Though clinical guidelines recommend genomic testing early on, it’s frequently delayed, prolonging ineffective treatments and expensive hospital visits. Evidence shows that introducing genomic sequencing earlier can cut healthcare expenses significantly—in epilepsy cases, by up to 61%, saving nearly $80,000 per child annually. This cost reduction reflects a shift from emergency care to focused outpatient management, benefiting Medicaid programs that shoulder much of this financial burden. The core obstacle is not technology but uneven adoption across regions and care settings. For a healthcare system aiming to balance quality and cost, expanding access to genomic sequencing offers a clear pathway to smarter, more effective care. Linda Genen, MD, MPH, Chief Medical Officer at GeneDx, emphasizes that this technology should be a standard part of care everywhere, not a privilege limited by location or resources.
Back
